<DOC>
	<DOCNO>NCT01064466</DOCNO>
	<brief_summary>Personalized Etoposide ( VP-16 ) chemotherapy target SCLC patient-specific biomarkers ( Single Nucleotide Polymorphisms - SNPs relative etoposide target , topoisomerase II CYP4503A4 ) Targeted SCLC chemotherapy Etoposide ( VP-16 ) patient-specific biomarkers ( SNPs ) Individualize personalize etoposide chemotherapy toward small cell lung cancer ( SCLC ) maximize effectiveness minimize risk via assay single nucleotide polymorphism ( SNPs ) relative etoposide target , topoisomerase II CYP4503A4 , base precisely sequence drug target ' gene . &lt; FDA IND 78,420 IND EXEMPT Letter &gt; -- -// -- - &lt; DHHS OHRP FWA00015357 &gt; -- -// -- - &lt; IORG0007849 &gt; -- -// -- - &lt; IRB00009424 &gt;</brief_summary>
	<brief_title>Retrospect Stage IND EXEMPT Clinical Study - Etoposide Single Nucleotide Polymorphisms</brief_title>
	<detailed_description>Targeted SCLC chemotherapy VP-16 personalize patient-specific biomarkers ( SNPs ) We obtain IND 78,420 Exemption Letter FDA like Drug Sponsor 04/29/2009 . In future , IND require conduct relative clinical study . // We obtain DHHS IRB approval document : Federal-wide Assurance ( FWA ) Protection Human Subjects Institutions within United States ( FWA : 00015357 ) . So develop relative clinical study USA . Our Further Retrospect Clinical Study use Combined Chemotherapy ETOPOSIDE INJECTION plus CARBOPLATIN INJECTION Combined Chemotherapy ETOPOSIDE INJECTION plus CISPLATIN INJECTION treat Small Cell Lung Cancer ( SCLC ) patient , try look relationship ETOPOSIDE INJECTION therapeutic efficacy Topoisomerase II SNP Genotyping , relationship ETOPOSIDE INJECTION therapeutic safety CYP4503A4 SNP Genotyping , base precisely sequence drug target ' gene . The treatment option must ETOPOSIDE INJECTION plus CARBOPLATIN INJECTION ETOPOSIDE INJECTION plus CISPLATIN INJECTION , specific SCLC patient , use ETOPOSIDE INJECTION ETOPOSIDE INJECTION plus CISPLATIN INJECTION right , survive 2 year . According Etoposide Injection Directions , Etoposide efficacy target may Topoisomerase II Etoposide metabolism target CYP4503A4 . // We hope discover Topoisomerase II SNP Genotypes could relative high therapeutic efficacy , CYP4503A4 SNP Genotypes could relative low therapeutic risk . We assay Single Nucleotide Polymorphisms ( SNPs ) Etoposide ( VP-16 ) drug target ( Topoisomerase II ) effectiveness-associated , assay Single Nucleotide Polymorphisms ( SNPs ) Etoposide ( VP-16 ) drug target ( CYP4503A4 ) risk-associated specific SCLC patient survive 2 year use Combined Chemotherapy ETOPOSIDE INJECTION plus CARBOPLATIN INJECTION Combined Chemotherapy ETOPOSIDE INJECTION plus CISPLATIN INJECTION , base precisely sequence drug target ' gene . In Retrospect Stage , 400 SCLC patient , use Combined Chemotherapy ETOPOSIDE INJECTION plus CISPLATIN INJECTION time since 2 year ago right , like usual approach group . // In Retrospect Stage , 400 SCLC patient , use Combined Chemotherapy ETOPOSIDE INJECTION plus CARBOPLATIN INJECTION time since 2 year ago right , like study approach group . // In Retrospect Stage , usual approach group 400 SCLC patient continue use Combined Chemotherapy ETOPOSIDE INJECTION plus CISPLATIN INJECTION . // In Retrospect Stage , study approach group 400 SCLC patient continue use Combined Chemotherapy ETOPOSIDE INJECTION plus CARBOPLATIN INJECTION . // All oncology drug must approve USA FDA must sell USA market legally . // The dosage oncology drug must abide label USA . We need use SCLC patient ' tissue humoral specimen assay Topoisomerase II SNP Genotypes CYP4503A4 SNP Genotypes precisely sequence drug target ' gene USA .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Small Cell Lung Carcinoma</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<criteria>Select 800 SmallCell Lung Cancer Patients Duration least 180 day The usual approach group Recruit 400 select specific SCLC patient still survive currently least 2 year use Combined Chemotherapy ETOPOSIDE INJECTION plus CISPLATIN INJECTION . ( The specific SCLC patient use Combined Chemotherapy ETOPOSIDE INJECTION plus CISPLATIN INJECTION time since least 2 year ago , right , still survive . ) The study approach group Recruit 400 select specific SCLC patient still survive currently least 2 year use Combined Chemotherapy ETOPOSIDE INJECTION.plus CARBOPLATIN INJECTION ( The specific SCLC patient use Combined Chemotherapy ETOPOSIDE INJECTION plus CARBOPLATIN INJECTION time since least 2 year ago , right , still survive . ) The inclusion criterion : 1.Clinical diagnosis small cell lung cancer 2.Survive 2 year use Combined Chemotherapy ETOPOSIDE INJECTION plus CARBOPLATIN INJECTION Combined Chemotherapy ETOPOSIDE INJECTION plus CISPLATIN INJECTION 3.Measurable disease 4.Adequate organ function 5.Adequate performance status 6.Age 22 year old 7.Sign informed consent form 8.Receive biopsy 9.Receive blooddrawing The exclusion criterion : 1.Pregnancy 2.Breastfeeding 3.The patient serious intercurrent illness infectious diseases 4.Have one different kind cancer time 5.Serious Allergy Lipids 6.Serious Bleed Tendency 7.The prohibition drug product</criteria>
	<gender>All</gender>
	<minimum_age>22 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>SCLC</keyword>
	<keyword>Etoposide</keyword>
	<keyword>SNP</keyword>
	<keyword>Topo</keyword>
	<keyword>CYP</keyword>
	<keyword>Genotype</keyword>
	<keyword>Oncology</keyword>
	<keyword>Genetics</keyword>
	<keyword>Lung</keyword>
	<keyword>Cancer</keyword>
</DOC>